Treatment-resistant Depression: Clinical Trials

4 trials for Treatment-resistant Depression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 4
Phase 21Completed 1

Follow Treatment-resistant Depression: new trials by email Literature Review of Treatment-resistant Depression trials Research Report on Treatment-resistant Depression

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant) - Treatment-resistant Depression
Phase 3CompletedJanssen Research & Development, LLC8022015-09-302025-04-29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Treatment-resistant Depression
Phase 3CompletedJanssen Research & Development, LLC3462015-08-102025-04-29
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Treatment-resistant Depression
Phase 3CompletedJanssen Research & Development, LLC2362015-08-072025-04-29
Action of Ketamine in Treatment-Resistant Depression
Ketamine, Midazolam - Treatment-resistant Depression
Phase 2 / Phase 3CompletedUniversity of Ottawa462013-05-012018-06-26

Narrower conditions

Depressive Disorder, Treatment-Resistant (4)  ·  Depression (1)

Broader conditions

Depressive Disorder (4)  ·  Mental Disorders (4)  ·  Mood Disorders (4)  ·  Behavior (1)  ·  Behavioral Symptoms (1)

Interventions

Antidepressive Agents (3)  ·  Duloxetine Hydrochloride (3)  ·  Escitalopram (3)  ·  Esketamine (3)  ·  Sertraline (3)  ·  Ketamine (1)  ·  Midazolam (1)

Sponsors

Janssen Research & Development, LLC (3)  ·  University of Ottawa (1)

Countries

United States (3)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Mexico (2)  ·  Poland (2)  ·  Spain (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Estonia (1)

Top investigators

Pierre Blier, M.D, Ph.D (1)

Results publications

PMID 32367114, PMID 32860422, PMID 33128208, PMID 34235612, PMID 34288609, PMID 34510411, PMID 34973081, PMID 35022754, PMID 36273682, PMID 37019044, PMID 38557430, PMID 30922101, PMID 31109201, PMID 31290965, PMID 32270176, PMID 32316080, PMID 34293233, PMID 34750057, PMID 34971723, PMID 35441931, PMID 35931041, PMID 36149841, PMID 36525338, PMID 37158911, PMID 38025416, PMID 38025433, PMID 39428602, PMID 39435126, PMID 41245530

NIH funding

2014 (3)